Hemideina Completes $10m Series A Capital Raise
Posted 21 October 2021 Hemideina, a private hearing technology company and BioMelbourne Network member, has successfully closed its $10 million Series A Capital Raise, managed by Henslow. The fully subscribed capital raising positions the company to build out…
ARCS Workforce and Capacity Summit Pre-Event Survey
Posted 21 October 2021 About the Survey BioMelbourne Network is participating in the ARCS Workforce and Capacity Summit 2021. In preparation for the summit, we would like to gather info from our membership via this survey. By collecting…
Joint Response to the HERC IP Framework Consultation
Posted: 20 October 2021 Research Australia, Medicines Australia, the Medical Technology Association of Australia (MTAA) and AusBiotech have responded to the HERC IP Framework Consultation paper. Together, they represent a significant proportion of the health R&D sector and…
WEHI and CSL to advance biologic therapies
Posted: 20 October 2021 Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a Centre for Biologic Therapies. The new Centre combines WEHI’s expertise in immunology, cancer, inflammatory…
Shopfront Activation Program
Posted 14 October 2021 The City of Melbourne is leading a precinct revitalisation program designed to support businesses and reinvigorate the key areas of the city that need it most, and we feel that this may be of…
ICN Supply Chain Survey to Shine Spotlight on MedTech Sector
Posted: 13 October 2021 The MedTech sector in Australia and New Zealand is worth annually around $6.5 billion and is growing! The Industry Capability Network is supported by the Victorian Government and we aim to “Help Local Win”.…
Brooker Consulting: Interim Executive Specialists
Posted 9 October 2021 Brooker Consulting have announced that Michelle Lyon has joined the team, specialising in interim executive appointments. Michelle has over 15 years’ experience in executive search, firstly partnering with FMCG and consumer-led businesses, then working…
Supporting founder of Bioshares, David Blake
The founder and editor of Bioshares, David Blake, needs our help In February, David was diagnosed with brain and lung cancer and he has been having treatment in Melbourne. With David’s family, biotechnology investor and public relations executive…
360biolabs opens Brisbane-based specialty lab
Posted: 1 October 2021 Their Brisbane laboratory enables 360biolabs to further support clinical trials in the north-east region of Australia. As Australia’s leading and most comprehensive specialty laboratory, 360biolabs often receives requests to process samples for downstream enzymatic…
Breakthrough research on pancreatic cancer
Posted: 30 September 2021 Amplia Therapeutics and The Garvan have released a scientific paper today, revealing breakthrough research that lowers pancreatic cancer’s resistance to chemotherapy by ‘priming’ cancer cells. The breakthrough Amplia is pleased to report the publication of a key…
World’s first four dimensional post-COVID lung imagery
Posted 29 September 2021 The world’s first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID’ providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been…
Cancer Therapeutics Unveils New Identity
Posted 29 September 2021 BioMelbourne Network member Cancer Therapeutics (CTx CRC Ltd) has unveiled its new name and brand identity – Canthera Discovery. This transformation forms part of a wider organisational strategy to continue the incredible legacy of…
